AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36328358 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1205
Number of subjects: 68
Study 33647373 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium lactate/potassium nitrate/hydroxylapatite toothpaste
Number of subjects: 0
Study 33647373 — intervention group
Group type: COMPARATOR
Intervention: Potassium nitrate control toothpaste
Number of subjects: 0
Study 32562153 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 37
Study 34536795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 56
Study 34536795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33017755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 381
Study 33017755 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR)
Number of subjects: 381
Study 36017744 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (additional 18-month treatment)
Number of subjects: 371
Study 36017744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (additional 18-month treatment)
Number of subjects: 371
Study 36017744 — intervention group
Group type: EXPERIMENTAL
Intervention: PVO > 45% at PE diagnosis
Number of subjects: 371
Study 36017744 — intervention group
Group type: EXPERIMENTAL
Intervention: sPAP > 56 mmHg at PE diagnosis
Number of subjects: 371
Study 36017744 — intervention group
Group type: EXPERIMENTAL
Intervention: PVO > 14% at 6 months
Number of subjects: 371
Study 36017744 — intervention group
Group type: EXPERIMENTAL
Intervention: sPAP > 34 mmHg at 6 months
Number of subjects: 371
Study 33909759 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy (guidance, therapeutic techniques, airway protection maneuvers, orofacial myofunctional and vocal exercises, diet introduction)
Number of subjects: 32
Study 33909759 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment (control group)
Number of subjects: 32
Study 33909759 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 32
Study 33444934 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone + fish oil (FO) (EPA 740 mg and DHA 400 mg daily)
Number of subjects: 46
Study 33444934 — intervention group
Group type: COMPARATOR
Intervention: risperidone + placebo
Number of subjects: 46
Study 34210727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-care intervention package
Number of subjects: 220
Study 34210727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 220
Study 32495933 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA ≥ 40.00 μmol/L
Number of subjects: 86
Study 32495933 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA threshold for phototherapy
Number of subjects: 86
Study 32495933 — intervention group
Group type: EXPERIMENTAL
Intervention: TBA threshold for preterm birth
Number of subjects: 86
Study 35014942 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial ankle-foot orthosis (AFO)
Number of subjects: 31
Study 35014942 — intervention group
Group type: COMPARATOR
Intervention: Lateral wedge insole
Number of subjects: 31
Study 34715908 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W)
Number of subjects: 317
Study 34715908 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg Q2W
Number of subjects: 317
Study 34715908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 32332459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 67
Study 32332459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 240 mg/d
Number of subjects: 67
Study 32332459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (both doses)
Number of subjects: 67
Study 33470861 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction-manipulation protocol
Number of subjects: 40
Study 33839578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic gingivitis
Number of subjects: 6544
Study 33839578 — intervention group
Group type: COMPARATOR
Intervention: No chronic gingivitis (Control)
Number of subjects: 6544
Study 34057858 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepractice-led assessment
Number of subjects: 14
Study 34057858 — intervention group
Group type: COMPARATOR
Intervention: In-person-led assessment
Number of subjects: 14
Study 34854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilume® drug-coated balloon (DCB)
Number of subjects: 127
Study 34854748 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic management (control)
Number of subjects: 127
Study 32150651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 32
Study 32150651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 35091313 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 7372
Study 35091313 — intervention group
Group type: COMPARATOR
Intervention: Shorter-duration enoxaparin
Number of subjects: 7372
Study 34474301 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended interval dosing (EID) of natalizumab (dosing intervals extended from 4 to 6 weeks)
Number of subjects: 30
Study 34474301 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of natalizumab (4-week intervals)
Number of subjects: 30
Study 33077341 — intervention group
Group type: COMPARATOR
Intervention: Peg–IFN–α2a 180 μg
Number of subjects: 86
Study 33077341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 270 μg
Number of subjects: 86
Study 33077341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 360 μg
Number of subjects: 86
Study 33077341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b 450 μg
Number of subjects: 86
Study 33077341 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study 35793664 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP + incentivized adherence and abstinence monitoring (n = 70)
Number of subjects: 141
Study 35793664 — intervention group
Group type: COMPARATOR
Intervention: BUP in usual care (control, n = 71)
Number of subjects: 141
Study 35793664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 34235736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality recess environment
Number of subjects: 352
Study 32296202 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-thickness tragal cartilage graft
Number of subjects: 40
Study 32296202 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 40
Study 34890563 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFMER Activity Score (SAS) version 2 (v2)
Number of subjects: 101
Study 33776375 — intervention group
Group type: EXPERIMENTAL
Intervention: Moviprep (Mp)
Number of subjects: 338
Study 33776375 — intervention group
Group type: COMPARATOR
Intervention: Prep Kit-C (Pc)
Number of subjects: 338
Study 33776375 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients with Moviprep (Mp)
Number of subjects: 338
Study 33776375 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-IBD patients with Moviprep (Mp)
Number of subjects: 338
Study 35325329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat loading (FL) with 250 ml of Ensure H® four hours before follow-up examination
Number of subjects: 20
Study 35325329 — intervention group
Group type: COMPARATOR
Intervention: Non-fat loading (non-FL)
Number of subjects: 20
Study 32080009 — intervention group
Group type: EXPERIMENTAL
Intervention: BGS-7 spacer
Number of subjects: 62
Study 32080009 — intervention group
Group type: COMPARATOR
Intervention: Titanium cage with autologous local bone
Number of subjects: 62
Study 35673948 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (20 mg/kg)
Number of subjects: 82
Study 35673948 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone (20 mg/kg)
Number of subjects: 82
Study 35673948 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone (20 mg/kg) followed by Levetiracetam
Number of subjects: 82
Study 32600210 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hit assembly technique
Number of subjects: 5
Study 32600210 — intervention group
Group type: COMPARATOR
Intervention: Three-hits assembly technique at low loads (4 kN)
Number of subjects: 5
Study 36482794 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC; 0.4 mg/g; n = 29)
Number of subjects: 66
Study 36482794 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content (NNC; 15.8 mg/g; n = 31)
Number of subjects: 66
Study 33399223 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder Checklist for DSM-5
Number of subjects: 220
Study 33399223 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness (Epworth Sleepiness Scale)
Number of subjects: 220
Study 32468187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Insulin
Number of subjects: 0
Study 32468187 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Insulin
Number of subjects: 0
Study 35791748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen (23%)
Number of subjects: 35
Study 35791748 — intervention group
Group type: COMPARATOR
Intervention: High oxygen (80% during induction and recovery, 40% during maintenance)
Number of subjects: 35
Study 35791748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 34147345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program of active aging (2 weekly sessions of 1h of exercise for 4 months, monthly health education sessions, and 3 days of social activities)
Number of subjects: 102
Study 34147345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program of active aging
Number of subjects: 102
Study 34147345 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular tips)
Number of subjects: 102
Study 32985410 — intervention group
Group type: EXPERIMENTAL
Intervention: No tympanomeatal flap approach (group A)
Number of subjects: 132
Study 32985410 — intervention group
Group type: COMPARATOR
Intervention: Tympanomeatal flap approach (group B)
Number of subjects: 132
Study 36006603 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable fitness trackers used for 12 weeks during CBT treatment
Number of subjects: 30
Study 36006603 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive exercise group (n = 17)
Number of subjects: 30
Study 36006603 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-maladaptive exercise group (n = 13)
Number of subjects: 30
Study 34621497 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy (EMDR)
Number of subjects: 101
Study 34621497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Writing Therapy (CBWT)
Number of subjects: 101
Study 34621497 — intervention group
Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 101
Study 35440302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 35440302 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 0
Study 33773111 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg vaccine (two-dose schedule)
Number of subjects: 950
Study 33773111 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg vaccine (two-dose schedule)
Number of subjects: 950
Study 33773111 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg vaccine (three-dose schedule)
Number of subjects: 950
Study 33773111 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg vaccine (three-dose schedule)
Number of subjects: 950
Study 33773111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two-dose schedule)
Number of subjects: 950
Study 33773111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three-dose schedule)
Number of subjects: 950
Study 33423318 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide 400 μg/day)
Number of subjects: 44
Study 33423318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of budesonide with oral statin (simvastatin 10 mg/day)
Number of subjects: 44
Study 33423318 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiments with budesonide and simvastatin
Number of subjects: 44
Study 33423318 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralisation of IL-10 with recombinant specific blocking antibody
Number of subjects: 44
Study 32539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLT2 inhibitor)
Number of subjects: 0
Study 32539810 — intervention group
Group type: COMPARATOR
Intervention: NPH Insulin
Number of subjects: 0
Study 36158699 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT) with a dose of 54 Gy in 27 fractions
Number of subjects: 116
Study 36158699 — intervention group
Group type: COMPARATOR
Intervention: Postoperative concurrent chemoradiotherapy (POCRT) with a dose of 50.4 Gy in 28 fractions combined with chemotherapy
Number of subjects: 116
Study 36158699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PORT and POCRT)
Number of subjects: 116
Study 33376119 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental calculus disruption solution (EXP‐955)
Number of subjects: 25
Study 33376119 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 25
Study 34048613 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT intervention for anxiety and/or depression
Number of subjects: 241
Study 33534342 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term SBP of 120-129 mmHg
Number of subjects: 3310
Study 33534342 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term SBP of 130-139 mmHg
Number of subjects: 3310
Study 33534342 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term SBP of 100-119 mmHg
Number of subjects: 3310
Study 33534342 — intervention group
Group type: COMPARATOR
Intervention: Long-term SBP of at least 140 mmHg
Number of subjects: 3310
Study 34563804 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural Sound Therapy (BST)
Number of subjects: 34
Study 34563804 — intervention group
Group type: COMPARATOR
Intervention: Music Therapy (MT)
Number of subjects: 34
Study 32331029 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (dose not specified) for 12 weeks in ARTISTS 1
Number of subjects: 266
Study 32331029 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (high or low dose, specific dosages not specified) for 8 weeks in ARTISTS 2
Number of subjects: 266
Study 32331029 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (open-label, single-arm) for long-term safety/tolerability
Number of subjects: 266
Study 32331029 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks in ARTISTS 1
Number of subjects: 266
Study 32331029 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks in ARTISTS 2
Number of subjects: 266
Study 35353052 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Coach (intervention group)
Number of subjects: 179
Study 35353052 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 179
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (150 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (400 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (800 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (600 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (1000 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (1250 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (1800 mg)
Number of subjects: 88
Study 34715032 — intervention group
Group type: EXPERIMENTAL
Intervention: M5717 (2100 mg)
Number of subjects: 88
Study 33190521 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 84
Study 33190521 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 84
Study 36067484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane (PLM)
Number of subjects: 60
Study 36449784 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM‐621
Number of subjects: 227
Study 36449784 — intervention group
Group type: COMPARATOR
Intervention: Control (hemostatic forceps)
Number of subjects: 227
Study 33655778 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-gene signature (Mammaprint)
Number of subjects: 6693
Study 33655778 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-analytic modeling approach
Number of subjects: 6693
Study 33655778 — intervention group
Group type: COMPARATOR
Intervention: MINDACT trial report
Number of subjects: 6693
Study 35396967 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg-1)
Number of subjects: 12
Study 35396967 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (placebo)
Number of subjects: 12
Study 34267242 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (45 min of incline walking)
Number of subjects: 30
Study 32840419 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial-Breast Irradiation (APBI) - 30 Gy in 5 once-daily fractions
Number of subjects: 520
Study 32840419 — intervention group
Group type: COMPARATOR
Intervention: Whole-Breast Irradiation (WBI) - 50 Gy in 25 fractions with a tumor bed boost
Number of subjects: 520
Study 35368768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure‐like stimulation and meditation over a 5 min period
Number of subjects: 65
Study 35368768 — intervention group
Group type: COMPARATOR
Intervention: Rest during the same 5 min period
Number of subjects: 65
Study 32623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schedule group (ESG) - reduced-frequency nurse-led, consultant-supervised clinic
Number of subjects: 207
Study 32623608 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule group (CSG) - reviewed as per UK guidelines
Number of subjects: 207
Study 32623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental follow-up (EFU)
Number of subjects: 207
Study 32623608 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (CFU)
Number of subjects: 207
Study 32623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-examination method of detection
Number of subjects: 207
Study 32623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-specific survival
Number of subjects: 207
Study 34547340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus Clonidine (LC)
Number of subjects: 40
Study 34547340 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus Saline Solution (LS)
Number of subjects: 40
Study 36028915 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Mizone
Number of subjects: 270
Study 36028915 — intervention group
Group type: COMPARATOR
Intervention: PEG + water
Number of subjects: 270
Study 32959582 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 60
Study 32959582 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 33276959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plating
Number of subjects: 0
Study 33276959 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary Nailing
Number of subjects: 0
Study 32891234 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller financial incentive (10,000 TZS; about US$4.50) for monthly clinic attendance
Number of subjects: 530
Study 32891234 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger financial incentive (22,500 TZS; about US$10.00) for monthly clinic attendance
Number of subjects: 530
Study 32891234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 530
Study 36056913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Tα1)
Number of subjects: 49
Study 36056913 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 49
Study 32792635 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant+iNO
Number of subjects: 100
Study 32792635 — intervention group
Group type: COMPARATOR
Intervention: iNO-Controls
Number of subjects: 100
Study 34647146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on radiomics and clinicopathological factors
Number of subjects: 223
Study 33606421 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinviewer
Number of subjects: 311
Study 33606421 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 311
Study 32652544 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 433
Study 32652544 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 433
Study 32652544 — intervention group
Group type: COMPARATOR
Intervention: CZP 400 mg Q2W (escape arm)
Number of subjects: 433
Study 34478390 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-triggered multistep model predictive control
Number of subjects: 0
Study 34478390 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistep parameter-dependent model predictive controller
Number of subjects: 0
Study 34478390 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation experiments on mass-spring-damping system
Number of subjects: 0
Study 34086150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated proton therapy (IMPT)
Number of subjects: 0
Study 34086150 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated photon (X-ray) radiotherapy (IMRT)
Number of subjects: 0
Study 35272533 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (human anti‐calcitonin gene‐related peptide receptor monoclonal antibody)
Number of subjects: 2985
Study 35272533 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 2985
Study 34098744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus docetaxel
Number of subjects: 0
Study 34098744 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (control)
Number of subjects: 0